Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors.
Our lead allogeneic candidate CYAD-101 is a NKG2D receptor-based CAR T, which incorporates our non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). We are also developing our short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM).
Our autologous CAR T franchise is evaluating our next generation NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Celyad Oncology’s headquarters and clinical manufacturing facility are located in Mont-Saint-Guibert, Belgium.
Celyad Oncology is committed to delivering innovative immunotherapies to patients with advanced cancer seeking novel treatment options
Mission & Vision
Developing innovative cell therapies against cancer
At Celyad Oncology, we are driven by the promise of delivering meaningful treatment options to patients seeking hope. Our goal is to discover, develop and commercialize our next-generation CAR T cell therapies. We are guided by our passion, led by our deep expertise in oncology and motivated by the patients we serve. We believe that our innovative CAR T candidates could offer patients with advanced disease alternative therapeutic options where no other treatments exist. Delivering best-in-class cell therapies for patients with unmet medical needs is our top priority.
At Celyad Oncology, our goal is to eliminate cancer and improve life.